156 related articles for article (PubMed ID: 1735078)
1. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Pazdur R; Ajani JA; Winn R; Bearden J; Belt RJ; Pilat S; Hallinan R; Levin B
Cancer; 1992 Feb; 69(4):878-82. PubMed ID: 1735078
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Pazdur R; Ajani JJ; Abbruzzese JL; Belt RJ; Dakhil SR; Dubovsky D; Graham S; Pilat S; Winn R; Levin B
Cancer; 1992 Oct; 70(8):2073-6. PubMed ID: 1394037
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Pazdur R; Ajani JA; Patt YZ; Gomez J; Bready B; Levin B
Cancer; 1993 Feb; 71(4):1214-8. PubMed ID: 8435795
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
[TBL] [Abstract][Full Text] [Related]
8. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
14. 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
John WJ; Neefe JR; Macdonald JS; Cantrell J; Smith M
Cancer; 1993 Dec; 72(11):3191-5. PubMed ID: 8242541
[TBL] [Abstract][Full Text] [Related]
15. Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study.
Lee KH; Lee JS; Suh C; Lee YS; Min YI; Ahn SH; Park KC; Kim SK; Kim SH
Am J Clin Oncol; 1992 Apr; 15(2):141-5. PubMed ID: 1553902
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
Bukowski RM; Inoshita G; Yalavarthi P; Murthy S; Gibson V; Budd GT; Sergi JS; Bauer L; Prestifilippo J
Cancer; 1992 Feb; 69(4):889-92. PubMed ID: 1735080
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
19. Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.
Kemeny N; Younes A
Semin Oncol; 1992 Apr; 19(2 Suppl 3):171-5. PubMed ID: 1557642
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296.
Wadler S; Brain C; Catalano P; Einzig AI; Cella D; Benson AB
Cancer J; 2002; 8(3):282-6. PubMed ID: 12074329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
